Clinical Trials Logo

Clinical Trial Summary

Respiratory distress syndrome (RDS) is a life-threatening condition for premature neonates. Antenatal glucocorticoids have been used clinically in women with threatened preterm birth to accelerate lung maturation for more than 40 years. The current treatment strategy for women with threatened preterm delivery is for a standard, "one size fits all" dosing with either betamethasone (BMZ) or dexamethasone. It is well known that pregnancy introduces additional variability in response to medication therapy with different physiological changes and alterations in the activity of drug metabolizing enzymes. The objective of this project is to evaluate the pharmacokinetic (PK), pharmacodynamic, and pharmacogenetic parameters of betamethasone (BMZ) and determine the differences in response and benefit in pregnancy. An individualized dosing approach to medications in pregnancy, such as BMZ, is crucial to optimize efficacy of this important medication.


Clinical Trial Description

After consent, a maternal sample of whole blood will be obtained for DNA isolation. Investigators will collect plasma samples at 4 time points on all participants. These will be done at baseline (pre-dose), and 0.5-2 hours, 4-6 hours, and 22-24 hours after the first dose of BMZ is administered. Investigators will obtain serum for estriol measurement on all participants before or within 2 hours of antenatal corticosteroid administration and about 24 hours after each dose is given (betamethasone is administered as 2 doses 24 hours apart). Investigators will obtain a saliva sample for measurement of estriol at the same times. Participants will be offered optional participation in a more detailed PK portion of the study. Participants who consent to this part of the study will have additional plasma samples obtained at a schedule of sampling of approximately 10-15 hours after the first dose and then 6-8 hours, 24, and 48 hours after the 2nd dose. One sample will be collected at each of these times. At the time of delivery, umbilical cord blood will be collected before being discarded for DNA, serum and plasma. Four placenta sections will be collected. A maternal blood sample will also be obtained for serum and plasma. If the investigators are unable to obtain umbilical cord blood, a buccal swab will be collected from the baby for DNA extraction. A chart review will be done on the infant within 30 days of birth to review and record neonatal outcomes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02793700
Study type Observational
Source Indiana University
Contact
Status Completed
Phase
Start date July 2016
Completion date March 2022

See also
  Status Clinical Trial Phase
Completed NCT00457925 - Absorption, Distribution, Metabolism And Excretion Study For GSK221149A Phase 1
Completed NCT05602883 - Music Therapy in the Threat of Premature Birth N/A
Completed NCT02451228 - Indomethacin PK and PD Therapy in Pregnancy
Not yet recruiting NCT00425867 - PAR Family Polymorphisms and Placental Invasion Disorders N/A
Terminated NCT00306462 - Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor N/A
Completed NCT00873314 - Bed Rest for Threatened Preterm Labor. Pilot Study N/A
Withdrawn NCT00120640 - Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate N/A
Completed NCT03223324 - Performance of the Monica Novii Wireless Patch System in Threatened and Actual Pre-Term Labour
Not yet recruiting NCT01022619 - The Association Between High Risk Pregnancy and Sleep-disordered Breathing N/A
Withdrawn NCT02569216 - Electrical Inhibition (EI): A Preliminary Study To Inhibit Preterm Labor And Preterm Birth Phase 1
Recruiting NCT05477381 - Cervical Softening and the Prediction of Preterm Birth
Completed NCT03057275 - Performance of the Monica Novii Wireless Patch System in Pre-term Labor